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ABSTRACT
Objectives To determine, first, the effects of menopausal status on circulating
calcitonin gene-related peptide (CGRP) levels and, second, the correlation between
circulating CGRP levels and biomarkers for cardiovascular disease.
Methods Cross-sectional study of healthy premenopausal and postmenopausal women
volunteers and women admitted for elective benign abdominal surgery in a district
general hospital. All women were non-smokers, had no history of endocrinological
problems and were not receiving any hormone therapy. Fasting blood samples
(premenopausal (n¼ 45): follicle stimulating hormone (FSH)5 20 IU/l, estradiol
(mean+ SEM) 440.33+ 51.82 pmol/l; postmenopausal women (n¼ 28):
FSH4 20 IU/l, estradiol 93.79+ 17.40 pmol/l) were analyzed for CGRP, resistin,
leptin, adiponectin, insulin and lipids using ELISA and immunoassays.
Results Mean circulating CGRP levels were higher in the postmenopausal women
compared with premenopausal women (pre: 41.79+ 9.01 pg/ml, post:
138.14+ 45.75 pg/ml; p¼ 0.047). Among women who were experiencing hot flushes,
the postmenopausal women had significantly higher CGRP levels than the premeno-
pausal women (pre: 21.98+ 4.95 pg/ml, post: 171.08+ 61.80 pg/ml; p¼ 0.028).
Serum CGRP levels positively correlated with serum insulin levels (r¼ 0.652,
p¼ 0.016) and HOMA index (r¼ 0.54, p5 0.001).
Conclusion These data show that circulating CGRP levels are influenced by
menopausal status and suggest additional mechanisms through which increased risk
of hyperinsulinemia and cardiovascular disease may arise in postmenopausal women.
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INTRODUCTION
Menopausal transition is associated with in-
creased risk of cardiovascular disease (CVD) in
women1. Estrogen deficiency leads to an unfavor-
able lipid profile2, which until recently had been
considered the main pathological phenomenon
responsible for development of atherosclerosis
and CHD. However, improvement in lipid profile
with hormone replacement therapy (HRT) does
not reduce cardiac disease events in clinical
studies3,4. Furthermore, recent evidence has
shown an increased risk of ischemic heart disease
and stroke in HRT users, demonstrating the
limited understanding of the pathogenesis of these
diseases5.
Calcitonin gene-related peptide (CGRP) is a
potent vasodilator and proinflammatory neuro-
peptide that plays an important role in maintain-
ing microvascular homeostasis. CGRP has been
linked to the development of CVD by promoting
myocardial injury via its own proinflammatory
properties, as well as by initiating or augmenting
other endogenous inflammatory mechanisms5,6.
Increased CGRP levels have been noted in subjects
with hypertension and myocardial infarction7,8
but the exact mechanism for this is uncertain.
Elevated CGRP serum levels have been ob-
served during hot flushes in postmenopausal
women and in men, following castration9–11,
linking acute release of CGRP with onset of
vasomotor symptoms. We have recently demon-
strated that CGRP is expressed in adipose tissue at
mRNA and protein level and that CGRP expres-
sion is higher in adipose tissue from postmeno-
pausal women, suggesting a potential mechanism
by which adipose tissue may contribute to the
increased prevalence and severity of vasomotor
symptoms12. Previously, animal studies have
shown higher tissue levels of CGRP in an
estrogen-deficient state13,14 suggesting that secre-
tion and activity of CGRP may be influenced by
the sex hormones. However, to date, there have
been no studies investigating the effect of natural
menopause on serum CGRP levels and whether
this is directly or indirectly associated with
vasomotor symptoms and CVD risk.
Postmenopausal women have an increased
tendency of visceral fat deposition, which, by
virtue of its proinflammatory and prothrombotic
properties, contributes to their risk of developing
the metabolic syndrome and CVD15. Adipose
tissue-derived proteins (adipokines), resistin, lep-
tin and adiponectin, provide a potential link
between obesity and the pathogenesis of CVD15.
Whilst studies have indicated sexual dimorphism
with regard to serum levels of these adipo-
kines16,17, reports as to the influence of menopau-
sal status remain conflicting18–20. Murine studies
have indicated resistin in obesity-associated in-
sulin resistance and type 2 diabetes mellitus21, but
current studies have been conflicting, with current
suggestions highlighting a proinflammatory role in
humans22. Leptin is also considered as a proin-
flammatory protein that may contribute to the
development of CVD through adverse affects on
vasculature23, by promoting arterial thrombosis24
and by stimulating production of reactive oxygen
species (ROS)25. In contrast, adiponectin, the anti-
inflammatory and antiatherogenic adipokine, is
positively associated with increased insulin sensi-
tivity26. Lower circulatory levels of adiponectin
are associated with increased severity of CVD and
can be used as a predictor for this27.
The combination of increased central obesity
and chronic low-grade inflammation appears to be
a mechanism for the pathogenesis of CVD28. This
was supported by the results from the Women’s
Health Initiative (WHI) study, demonstrating
white cell count and C-reactive protein (CRP) as
the strongest predictors for cardiovascular mor-
bidity and mortality in postmenopausal women29.
As such, this may have implications for post-
menopausal women with an increase in CVD risk.
Therefore, the aim of this study was, first, to
determine the effects of menopausal status on
serum CGRP, resistin, leptin, adiponectin and
anthropometric factors, through analysis of the
differences in mean serum levels in premenopausal
and postmenopausal women and, second, to
determine the influence of CGRP on cardiovas-
cular health in postmenopausal women, by
examining the correlation between serum CGRP
levels and known markers of CVD.
MATERIALS AND METHODS
Subjects
For these studies, fasting blood samples were
obtained from premenopausal and postmenopau-
sal women (n¼ 73: premenopausal 45, postme-
nopausal 28). The postmenopausal status was
defined as amenorrhea for more than 12 months,
with serum follicular stimulating hormone (FSH)
levels4 20 IU/l. Subjects with any medical con-
dition (i.e. hypertension, CVD, thyroid disorders,
renal disorders, diabetes or chronic pain condi-
tions) were excluded from the study. None of the
subjects were on endocrine therapy (i.e. HRT,
tamoxifen, steroids or antiglycemic agents) or any
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medication that might have influenced CGRP
secretion. All samples were collected in accor-
dance with the research protocol approved by the
Solihull Local Research Ethics Committee.
Collection of clinical data
Anthropometric data were collected to calculate
body mass index (BMI) and waist/hip ratio
(WHR). Women with a BMI between 18 and
24.9 kg/m2 were classified as normal, 25–29.9 kg/
m2 as overweight and a BMI of 30 kg/m2 as
obese. Systolic and diastolic blood pressures were
recorded for each subject in the sitting position.
The date of the last menstrual period, cycle length
and regularity were recorded to determine the
phase of the menstrual cycle in premenopausal
women. Women who were within the last 2 weeks
of their cycle were classified as being in the luteal
phase (n¼ 17) and women who were in the earlier
part of their cycle were classified as being in the
follicular phase (n¼ 21). All women were asked if
they were experiencing hot flushes and the average
number of hot flushes experienced per week was
recorded. The women experiencing hot flushes
were asked to indicate the level of distress caused
by hot flushes on a scale of 0–10, 0 being no
distress at all and 10 being the most severe distress
(10-point Likert scale). Data were analyzed as
interval data.
Collection, storage and analysis
of blood samples
Blood samples were collected after a minimum of
6 h fasting. The samples were immediately pro-
cessed, the sera separated and stored at 770C
until required. All serum samples were analyzed
for estradiol, FSH, glucose, insulin, total choles-
terol, triglyceride, low density lipoprotein (LDL)
and high density lipoprotein (HDL) and CGRP
levels. Additionally, samples were analyzed for
leptin (n¼ 56: premenopausal 31, postmenopau-
sal 25), resistin (n¼ 61: premenopausal 35,
postmenopausal 26) and adiponectin (n¼ 66:
premenopausal 39, postmenopausal 27) levels.
Estradiol and FSH levels were determined using
electrochemiluminescence immunoassays (Roche
Diagnostics, USA) (estradiol reference range 18.4–
15 781 pmol/l, coefficients of variation (CV)
intra-batch 5.7%, inter-batch 6.2%; FSH refer-
ence range 0.1–200 IU/l, CVs intra-batch 2.8%,
inter-batch 4.5%). The sample for serum glucose
was collected into a fluoride oxalate tube and
analyzed using an automated colorimetric method
(Roche Diagnostics) (reference range 0.11–
25 mmol/l, CVs intra-batch 0.9%, inter-batch
1.8%). Serum insulin levels were determined using
a solid-phase enzyme amplified sensitivity immu-
noassay (Linco Research Inc. Missouri, USA)
(sensitivity 2 mU/ml, range 2–200 mU/ml, CVs
intra-assay 5.96%, inter-assay 10.3%). HOMA
scores were calculated as fasting glucose
(mmol/l)6 fasting insulin (mIU/ml)/22.5.
The total cholesterol, serum triglyceride and
HDL levels were determined using an automated
colorimetric method (Roche Diagnostics, USA)
(triglyceride reference range 0.05–11.3 mmol/l,
CVs intra-batch 1.5%, inter-batch 1.8%; total
cholesterol reference range 0.08–20.7 mmol/l, CV
intra-batch 0.8%, inter-batch 1.7%; HDL refer-
ence range 0.08–3.11 mmol/l, CVs intra-batch
0.9%, inter-batch 1.85%). The serum LDL cho-
lesterol concentration was calculated using the
Freidwald approximation: LDL cholesterol¼ total
cholesterol - HDL cholesterol - (triglycerides/
2.22) mmol/l.
The analysis for determination of CGRP (ALP-
CO Diagnostics, Windham, USA), estrone (ALP-
CO Diagnostics), leptin (LINCO Research,
Missouri, USA), resistin (R&D Systems Abingdon,
UK) and adiponectin (LINCO Research) was
performed by solid-phase enzyme amplified sensi-
tivity immunoassay (CGRP sensitivity 2 pg/ml,
CVs intra-assay 2.7–25%, inter-assay 0.7–16.6%;
estrone sensitivity 10 pg/ml, CVs intra-assay 6.7–
9.1%, inter-assay 6.9–11.7%,; leptin sensitivity
0.5ng/ml, CV intra-assay 2.6–4.6% inter-assay
2.6–6.2%; resistin sensitivity 0.026 ng/ml, CVs
intra-assay 3.8–5.3%, inter-assay 7.8–9.2%,; adi-
ponectin sensitivity 0.78 ng/ml, CV intra -assay
0.9–7.4%, inter-assay 2.4–8.4%). All samples
were analyzed in duplicate and an equal number
of pre- and postmenopausal samples were loaded
onto each plate. Those results showing more than
10% intra -test variations were repeated.
Statistical analysis
Statistical analysis was performed using SPSS
statistical software package 12.0.1 (SPSS Inc.).
Student t tests have been performed to analyze
differences in the mean between groups. A
Pearson correlation coefficient was calculated for
continuous variables. The data showing non-
normal distribution were logged prior to calculat-
ing correlation coefficients. The significance
threshold has been taken as p5 0.05. The data
have been presented as mean+ standard equiva-
lent of the mean, unless stated otherwise.
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RESULTS
Baseline characteristics
Mean age, BMI, WHR, serum estradiol and FSH
levels of pre- and postmenopausal groups are
shown in Tables 1 and 2. As expected, the post-
menopausal women were older, had lower serum
estradiol levels, lower estrone levels and higher
serum FSH levels. The two groups were compar-
able in terms of mean systolic blood pressure,
diastolic blood pressure and fasting glucose and
insulin levels (Table 1). There were more women in
the normal-weight category in the premenopausal
group. The mean BMI was comparable in the
overweight and the obese categories in pre- and
postmenopausal women (Table 2). Age was inver-
sely correlated with WHR (r¼ 0.236, p¼ 0.04),
i.e. a weak correlation was observed between
central adiposity and increasing age. Age was
negatively correlated with serum estradiol
(r¼70.407, p5 0.001) and positively correlated
with serum FSH levels (r¼ 0.582, p5 0.001), i.e.
older women had lower estradiol and higher FSH
levels.
Hot flushes
Among postmenopausal women, 60.7% reported
having hot flushes, with an average distress score
of 3.72, whilst 15.6% of premenopausal women
reported having hot flushes with a similar distress
score (3.71). All except one of the premenopausal
women, who reported hot flushes, were above the
age of 43 years. All premenopausal women had
serum FSH5 20 IU/l (mean 6.89+ 1.06 IU/l)
and serum estradiol levels within the normal
range (mean 434.29+ 146.88 pmol/l). The
postmenopausal women had a significantly higher
average number of hot flushes per week (premeno-
pausal: 1.84+ 1.1; postmenopausal: 12.1+ 3.3,
p¼ 0.006). Analyzing the study population as a
whole, the women experiencing hot flushes had
higher mean BMI and WHR compared with the
women who were not experiencing any hot flushes
(Table 3). The mean estradiol level was lower and
mean FSH level was higher in women experiencing
hot flushes (Table 3). There was a positive cor-
relation between the number of hot flushes experi-
enced per week with the serum FSH (r¼70.292,
p¼ 0.013). Similarly, a negative correlation was
observed between the number of hot flushes and
serum estrone levels (r¼70.268, p¼ 0.022).
CGRP
Mean serum CGRP levels were three-fold
higher in the postmenopausal women compared
with the premenopausal women (postmeno-
pausal: 138.14+ 45.75 pg/ml; premenopausal:
41.79+ 9.01 pg/ml; p¼ 0.047) (Figure 1). In
premenopausal women, mean serum CGRP levels
did not differ significantly with respect to the
menstrual phase (follicular: 46.38+ 12.05 pg/ml;
luteal: 25.76+ 2.55 pg/ml, not significant).
Among women who were having hot flushes, the
postmenopausal women had significantly higher
CGRP levels than the premenopausal women
(postmenopausal: 171.08+ 61.80 pg/ml; preme-
nopausal: 21.98+ 4.95 pg/ml; p¼ 0.028). There
was no difference in mean CGRP levels among
pre- and postmenopausal women who were not
having any hot flushes. The subgroup analysis did
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Table 1 Baseline characteristics of premenopausal and postmenopausal groups of women. Results are shown as
mean+ standard equivalent of the mean unless stated as standard deviations (SD). Independent Student t tests were
used to compare groups
Premenopausal (n¼ 45) Postmenopausal (n¼ 28) p Value
Age (years)+ SD 41.22+6.58 57.00+ 9.24 50.001
Waist/hip ratio 0.81+0.01 0.82+ 0.01 0.191
Body mass index (kg/m2)+ SD 26.81+5.02 27.82+ 3.91 0.370
Mean systolic BP (mmHg) 123.51+2.54 127.71+ 3.04 0.299
Mean diastolic BP (mmHg) 73.40+1.35 76.21+ 1.86 0.216
Serum estradiol (pmol/l) 440.33+51.82 93.79+ 17.40 50.001
Serum estrone (pg/ml) 338.77+28.07 233.61+ 36.31 50.001
Estrone/estradiol ratio 1.12+0.120 3.51+ 0.70 0.001
Serum FSH (IU/l) 6.08+0.46 77.67+ 7.28 50.001
Serum glucose (mmol/l) 4.89+0.09 4.83+ 0.08 0.689
Serum insulin (mU/ml) 7.39+0.98 7.68+ 1.29 0.855
HOMA index 1.64+0.24 1.77+ 0.31 0.853
BP, blood pressure; FSH, follicle stimulating hormone
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not show any significant difference in mean CGRP
levels with respect to BMI.
Serum CGRP levels correlated positively with
fasting insulin levels (r¼ 0.394, p¼ 0.002)
(Figure 2) and HOMA index (r¼ 0.540,
p50.001). The correlation with insulin and
HOMA index increased significantly (r¼ 0.652,
p¼ 0.016; r¼ 0.679, p¼ 0.011, respectively) when
age, BMI and menopausal status were adjusted for.
Lipid profile
As expected, the postmenopausal women had an
unfavorable lipid profile compared with the
premenopausal women. The postmenopausal wo-
men had higher mean serum total cholesterol,
triglyceride and LDL levels (Table 4). Further-
more, total cholesterol, triglyceride and serum
LDL levels were significantly higher in the obese
women compared with the women with normal
BMI (p¼ 0.009, p¼ 0.007, p¼ 0.018, respec-
tively). Serum cholesterol correlated positively
with age, BMI and WHR. Serum triglyceride and
LDL levels also showed similar correlations. The
mean serum HDL levels were comparable in the
two groups and no significant correlation was
observed between serum HDL and age or BMI.
Serum cholesterol levels were negatively corre-
lated with serum estradiol and positively corre-
lated with serum FSH levels (r¼70.358,
p¼ 0.003; r¼ 0.475, p5 0.001). Serum triglycer-
ide levels showed similar trends.
Leptin, resistin and adiponectin
The leptin levels were two-fold greater in the
obese women compared with the women with
normal BMI (normal BMI: 19.68+ 3.41 ng/ml;
obese: 53.44+ 6.06 ng/ml, p5 0.001). This ef-
fect was seen in both premenopausal and post-
menopausal groups, although there were no
significant differences in the mean leptin or
resistin levels between premenopausal and post-
menopausal subgroups (Table 4). Strong positive
correlations were observed between serum leptin
levels and BMI (r¼ 0.625, p5 0.001), serum
cholesterol (r¼ 0.325, p¼ 0.019), serum triglycer-
ide (r¼ 0.301, p¼ 0.03) and LDL levels
(r¼ 0.294, p¼ 0.038). Serum leptin levels also
correlated positively with serum insulin levels
(r¼ 0.468, p¼ 0.001) and the HOMA index
(r¼ 0.398, p¼ 0.004). In addition, serum adipo-
nectin levels were strongly correlated with WHR
(r¼70.649, p¼ 0.016) and serum HDL levels
(r¼ 0.925, p5 0.001), when age, BMI and
menopausal status were controlled for. However,
there was no significant difference between serum
adiponectin levels in premenopausal and postme-
nopausal groups (Table 4). The mean adiponectin
level did not differ between women with normal
BMI and the obese group.
DISCUSSION
The present study investigated the influence of
menopausal status and adiposity on CGRP levels,
in order to evaluate CGRP’s role in cardiovascular
risk, postmenopause. The findings from these
studies determined that postmenopausal status
significantly increased circulating CGRP levels,
whilst the state of insulin resistance also affected
CGRP levels. As the first study to identify a
positive correlation between serum CGRP and
fasting insulin levels, our findings support the
previously reported antagonistic effect of CGRP
on insulin action30 and, thus, a potential mechan-
ism by which CGRP may have an adverse
influence on cardiovascular health in postmeno-
pausal women.
The results of our studies demonstrating in-
creased CGRP levels in postmenopausal women,
especially those still experiencing hot flushes, are
in accord with previous clinical data that demon-
strated increased CGRP secretion during hot
flushes31. It is tempting to speculate that the
increased serum CGRP levels are associated with
the occurrence of hot flushes as there was no
difference in the mean serum CGRP levels in pre-
and postmenopausal women who did not have hot
flushes. However, further work in a larger group
of symptomatic women would be required to
establish a causative effect. Furthermore, animal
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Table 2 Distribution according to body mass index (BMI) category. Results are shown as mean+ standard
deviation (SD). Independent Student t tests were used to compare groups
BMI category Premenopausal n (mean+ SD) Postmenopausal n (mean+ SD) p Value
18–24.9 kg/m2 16 (22.7+ 1.45) 7 (24.24+ 1.35) 0.03
25–29.9 kg/m2 18 (26.97+ 1.61) 15 (27.03+ 1.57) 0.98
30 kg/m2 10 (34+ 4.22) 6 (33.98+ 2.84) 0.92
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studies have shown higher CGRP expression and
secretion in the estrogen-deficient state13,14. Con-
flicting findings have also been reported in a
previous study by Valentini and co-workers, where
CGRP levels were shown to be lower in post-
menopausal women. Such differences may have
arisen due to the smaller number of participants in
Valentini’s study (n¼ 15)32 as well as differences
in the study population in terms of time since
menopause, presence of significant vasomotor
symptoms and use of exogenous hormones –
factors which may have affected the CGRP levels.
All we can speculate is that the increased CGRP
serum levels in postmenopausal women were
related to hot flushes.
Within our study there was an apparent lack of
linear correlation between serum CGRP and
serum estradiol or estrone levels, or with the
number of hot flushes. This finding was not
unexpected as the majority of participants in this
study were either asymptomatic or they were
experiencing mild vasomotor symptoms, needing
no treatment. Although 61% of postmenopausal
women in this study group reported hot flushes,
which is consistent with the general population33,
a significant proportion (16%) of the premeno-
pausal women also reported hot flushes, despite
adequate serum estradiol and normal FSH levels.
This suggests that circulating estradiol levels do
not predict the occurrence or the severity of hot
flushes. This may be due to the short circulatory
half-life and rapid enzymatic degradation of
CGRP, which may not allow circulatory levels to
accurately reflect tissue levels34. Similarly, the
serum estrogen levels in postmenopausal women
may not be a valid indicator of the tissue
bioavailability due to the varying level of its local
production35. As such, the results indicate that
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Figure 1 Mean serum calcitonin gene-related peptide
(CGRP) levels (pg/ml) in premenopausal and postme-
nopausal women
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more than one mechanism is involved in the
pathogenesis of hot flushes.
The results from this study support the recent
findings of increased frequency and severity of hot
flushes in women with higher BMI36, thus
challenging the common belief that obese women
experience less vasomotor symptoms. Further-
more, the women with higher WHR, i.e. women
with higher central adiposity, had worse symp-
toms, suggesting a possible role for visceral fat in
the pathogenesis of hot flushes. However, to date,
the mechanisms underlying this phenomenon
remain undetermined.
From our studies, it is clear that the subjects, as
previously noted, have shown an age-related
increase in WHR37, an unfavorable lipid profile
in the postmenopausal group and increased total
cholesterol, triglyceride and LDL serum levels with
increasing BMI and WHR. All these factors
support the known association of worsening
metabolic syndrome with central adiposity in
postmenopausal women. Previous longitudinal
studies have shown a slight decrease in serum
HDL levels during the menopausal transition,
which remains unaffected by increasing age38.
However, the lack of this effect in our study is
possibly due to the comparable BMI in the two
groups, which has a strong influence on serum
HDL levels. Our study shows that circulating
leptin, resistin and adiponectin levels remained
unaffected by menopausal status. Whilst adipokine
secretion is strongly influenced by body fat content
and distribution, the apparent lack of change in
circulating levels in pre- and postmenopausal
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Figure 2 The linear correlation between serum calcitonin gene-related peptide (CGRP) and fasting serum insulin
levels in the whole cohort of premenopausal (Pre, n¼ 45) and postmenopausal (Post, n¼ 28) women (r represents
Pearson correlation coefficient). The values of both serum CGRP and insulin were log transformed for analysis
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Table 4 Serum lipid profile, adipokines and endotoxin levels in premenopausal and postmenopausal groups of
women. Results are shown as mean+ standard equivalent of the mean (n). Independent Student t tests were used to
compare groups
Premenopausal Postmenopausal p Value
Total cholesterol (mmol/l) 4.77+0.14 (45) 5.97+0.23 (28) 50.001
LDL cholesterol (mmol/l) 2.68+0.12 (45) 3.49+0.22 (28) 0.002
HDL cholesterol (mmol/l) 1.70+0.08 (45) 1.83+0.09 (28) 0.276
Triglycerides (mmol/l) 0.87+0.06 (45) 1.36+0.17 (28) 0.009
Leptin (ng/ml) 31.52+4.09 (31) 31.48+4.28 (25) 0.995
Resistin (ng/ml) 14.37+0.65 (35) 13.37+0.58 (26) 0.276
Adiponectin (mg/ml) 11.86+0.88 (39) 14.12+1.07 (27) 0.108
LDL, low density lipoprotein; HDL, high density lipoprotein
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subjects is not surprising, as the groups were BMI-
and WHR-matched.
In conclusion, these data highlight that circulat-
ing CGRP levels appear to be influenced by
menopausal status and suggest additional me-
chanisms may contribute to the increased risk of
hyperinsulinemia and cardiovascular disease in
postmenopausal women.
ACKNOWLEDGEMENTS
We would like to thank our colleagues in the
Solihull hospital for their help in collecting
samples and all the women who volunteered to
participate in the study.
Conflict of interest Nil.
Source of funding This study was funded by
the Menopause Research Trust Fund, Solihull
Hospital, West Midlands, UK. We also thank the
MRF Arden Fellowship for supporting Dr Alison
Harte.
References
1. Gordon T, Kannel WB, Hjortland MC, et al.
Menopause and coronary heart disease: the
Framingham study. Ann Intern Med 1978;89:
157–61
2. Stevenson JC, Crook D, Godsland IF. Influence
of age and menopause on serum lipids and
lipoproteins in healthy women. Atherosclerosis
1993;98:83–90
3. Manson JE, Hsia J, Johnson KC, et al. Women’s
Health Initiative Investigators. Estrogen plus
progestin and the risk of coronary heart disease.
N Engl J Med 2003;349:523–34
4. Grady D, Herrington D, Bittener V, et al.
HERS Research Group. Cardiovascular disease
outcomes during 6.8 years of hormone therapy:
Heart and Estrogen/progestin Replacement
Study follow-up (HERII). JAMA 2002;288:49–
57
5. Watson RE, Supowit SC, Zhao H, et al. Role of
sensory nervous system vasoactive peptides in
hypertension. Braz J Med Biol Res 2002;35:
1033–45
6. Madeddu P, Emanueli C, Bonaria SM, et al. Role
of calcitonin gene-related peptide and kinins in
post-ischemic intestinal reperfusion. Peptides
2001;22:915–22
7. Chu DQ, Choy M, Foster P, et al. A comparative
study of the ability of calcitonin gene-related
peptide, and adrenomedullin (13-52) to mod-
ulate microvascular but not thermal hyperalgesia
responses. Br J Pharmocol 2000;130:1589–96
8. Hsu JH, Yeh JL, Dai ZK, et al. Increased
circulating calcitonin gene-related peptide in
congestive heart failure caused by congenital
heart disease. Int Heart J 2005;46:867–75
9. Chen JT, Hirai Y, Seimiya Y. Menopausal
flushes and calcitonin-gene-related peptide. Lan-
cet 1993;342:49
10. Wyon Y, Spetz AE, Theodorsson GE, Hammar
ML. Concentration of calcitonin gene-related
peptide and neuropeptide Y in plasma increases
during flushes in postmenopausal women. Me-
nopause 2000;7:25–30
11. Spetz AE, Pettersson B, Varenhorst E, Theo-
dorsson E, Thorell LH, Hammar ML. Momen-
tary increase in plasma calcitonin gene related
peptide is involved in hot flashes in men treated
with castration for carcinoma of the prostate.
J Urol 2001;166:1720–3
12. Gupta P, Harte AL, da Silva NF, et al. Expres-
sion of calcitonin gene-related peptide, adreno-
medullin, and receptor modifying proteins in
human adipose tissue and alteration in their
expression with menopause status. Menopause
2007;14:1031–8
13. Pardutz A, Multon S, Malgrange B, et al. Effect
of systemic nitroglycerin on CGRP and 5-HT
afferents to rat caudal spinal trigeminal nucleus
and its modulation by estrogen. Eur J Neurosci
2002;15:1803–9
14. Moussaoul S, Duval P, Lenoir V, et al. CGRP in
trigeminal nucleus, spinal cord and hypothala-
mus: effect of gonadal steroids. Neuropeptides
1996;30:546–50
15. Berg AH, Scherer PE. Adipose tissue, inflamma-
tion and cardiovascular disease. Circ Res
2005;96:939–49
16. Silha JV, Krsek M, Skrha JV, et al. Plasma
resistin, adiponectin and leptin levels in lean and
obese subjects: correlations with insulin resis-
tance. Eur J Endocrinol 2003;149:331–5
17. Baratta R, Amato S, Degano C, et al. Adipo-
nectin relationship with lipid metabolism is
independent of body fat mass: evidence from
both cross-sectional and intervention studies.
J Clin Endocrinol Metab 2004;89:2665–71
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
CGRP and insulin in menopause Gupta et al.
8 Climacteric
18. Rosenbaum M, Nicolson M, Hirsch J, et al.
Effects of gender, body composition, and meno-
pause on plasma concentrations of leptin. J Clin
Endocrinol Metab 1996;81:3424–7
19. Gavrila A, Chan JL, Yiannakouris N, et al.
Serum adiponectin levels are inversely associated
with overall and central fat distribution but are
not directly regulated by acute fasting or leptin
administration in humans: cross-sectional and
interventional studies. J Clin Endocrinol Metab
2003;88:4823–31
20. Milewicz A, Zatonska K, Demissie M, et al.
Serum adiponectin concentration and cardiovas-
cular risk factors in climacteric women. Gyecol
Endocrinol 2005;20:68–73
21. Kusminski CM, McTernan PG, Kumar S. Role
of resistin in obesity, insulin resistance and type
II diabetes. Clin Sci 2005;109:243–56
22. Vendrell J, Broch M, Vilarrasa N, et al. Resistin,
adiponectin, ghrelin, leptin, and proinflamma-
tory cytokines: relationships in obesity. Obes
Res 2004;12:962–71
23. Singhal A, Farooqi IS, Cole TJ, et al. Influence of
leptin on arterial distensibility: a novel link
between obesity and cardiovascular disease?
Circulation 2002;106:1919–24
24. Konstantinides S, Schafer K, Loskutoff DJ. The
prothrombotic effects of leptin possible implica-
tions for the risk of cardiovascular disease in
obesity. Ann N Y Acad Sci 2001;947:134–41
25. Xu FP, Chen MS, Wang YZ, et al. Leptin
induces hypertrophy via endothelin-1-reactive
oxygen species pathway in cultured neonatal rat
cardiomyocytes. Circulation 2004;110:1269–75
26. Singhal A, Jamieson N, Fewtrell M, et al.
Adiponectin predicts insulin resistance but not
endothelial function in young, healthy adoles-
cents. J Clin Endocrinol Metab 2005;90:4615–
21
27. Pilz S, Maerz W, Weihrauch G, et al. Adipo-
nectin serum concentrations in men with cor-
onary artery disease: The Ludwigshafen Risk in
cardiovascular Health (LURIC) study. Clin
Chim Acta 2006;364:251–5
28. Hansson GK. Inflammation. Atherosclerosis,
and coronary artery disease. N Engl J Med
2005;352:1685–95
29. Margolis KL, Manson JE, Greenland P, et al.
Women’s Health Initiative Research Group.
Leukocytes count as a predictor of cardiovas-
cular events and mortality in postmenopausal
women: the Women’s Health Initiative Observa-
tional Study. Arch Intern Med 2005;165:500–8
30. Choi SB, Frontoni S, Rossetti L. Mechanism by
which calcitonin gene-related peptide antago-
nizes insulin action in vivo. Am J Physiol
1991;260:E321–5
31. Wyon Y, Spetz AE, Theodorsson GE, et al.
Concentration of calcitonin gene-related peptide
and neuropeptide Y in plasma increases during
flushes in postmenopausal women. Menopause
2000;7:25–30
32. Valentini A, Petraglia F, Vita DD, et al. Changes
of plasma calcitonin gene-related peptide levels
in postmenopausal women. Am J Obstet Gyne-
col 1996;173:638–42
33. McKinlay SM, Jefferys M. The menopausal
syndrome. Br J Prevent Soc Med 1974;28:108–
15
34. Le Greves P, Nyberg F, Hokfelt T, et al.
Calcitonin gene-related peptide is metabolized
by an endopeptidase hydrolyzing substance P.
Regul Pept 1989;25:277–86
35. Simpson E, Rubin G, Clyne C, et al. Local
estrogen biosynthesis in males and females.
Endocr Relat Cancer 1999;6:131–7
36. Gallicchio L, Visvanathan K, Miller SR, et al.
Body mass, estrogen levels, and hot flashes in
midlife women. Am J Obstet Gynecol 2005;193:
1353–60
37. Kotani K, Tokunaga K, Fujioka S, et al. Sexual
dimorphism of age-related changes in whole-
body fat distribution in the obese. Int J Obes
Relat Metab Disord 1994;18:207
38. Matthews KA, Meilahn E, Kuller LH, et al.
Menopause and risk factors for coronary heart
disease. N Engl J Med 1989;321:641–6
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
CGRP and insulin in menopause Gupta et al.
Climacteric 9
